



DEC 18 2001

Ms. Robin Weiner  
Vice President, Clinical  
and Regulatory Affairs  
Quidel Corporation  
10165 McKellar Court  
San Diego, CA 92121

### Categorization Notification

Regulations codified at 42 CFR 493.15 et. seq., implementing the Clinical Laboratory Improvement Amendments of 1988, require the Secretary to provide for the categorization of specific clinical laboratory test systems by the level of complexity. Based upon these regulations, the following commercially marketed test system or assay for the analytes is categorized below:

Test system name: QUIDEL QUICKVUE+ INFECTIOUS MONONUCLEOSIS (WHOLE BLOOD)

Analyte name: INFECTIOUS MONONUCLEOSIS ANTIBODIES (MONO)

Re: K902510/A001

Complexity: WAIVED

This complexity categorization is effective as of the date of this notification. This categorization will be reported on FDA's home page <http://www.fda.gov/cdrh/clia>. This categorization information may be provided to the user of the commercially marketed test system or assay as specified for the analyte indicated. This categorization will also be announced in a Federal Register Notice, which will provide opportunity for comment on the decision. FDA reserves the right to reevaluate and recategorize this test based upon the comments received in response to the Federal Register Notice. For questions regarding FDA's categorization procedure, contact Clara A. Sliva, Acting CLIA Coordinator, at (301) 827-0496 or email <http://www.CLIA@CDRH.FDA.GOV>.

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Device  
Office of Device Evaluation  
Center for Devices and Radiological Health